NCT02953665View on ClinicalTrials.gov

Safety and Efficacy of Liraglutide in Parkinson's Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

63

Participants

Timeline

Start Date

April 3, 2017

Primary Completion Date

August 3, 2022

Study Completion Date

August 3, 2022

Conditions

Parkinson Disease

Interventions

DRUG

Liraglutide

Liraglutide 6 mg/ml once daily at a maximum dose of 1.8 mg

DRUG

Placebo

Placebo (for Liraglutide) 6 mg/ml once daily at a maximum dose of 1.8 mg

Trial Locations (1)

90048

Cedars Sinai Medical Center, Los Angeles

Sponsors

Collaborators (1)

Novo Nordisk A/S

All Listed Sponsors

collaborator

Cure Parkinson's

OTHER

collaborator

Novo Nordisk A/S

INDUSTRY

lead

Cedars-Sinai Medical Center

OTHER